dc.contributor.author | Trimboli, RM | |
dc.contributor.author | Giorgi Rossi, P | |
dc.contributor.author | Battisti, NML | |
dc.contributor.author | Cozzi, A | |
dc.contributor.author | Magni, V | |
dc.contributor.author | Zanardo, M | |
dc.contributor.author | Sardanelli, F | |
dc.date.accessioned | 2020-10-21T08:42:41Z | |
dc.date.issued | 2020-09-25 | |
dc.identifier.citation | Insights into imaging, 2020, 11 (1), pp. 105 - ? | |
dc.identifier.issn | 1869-4101 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/4179 | |
dc.identifier.eissn | 1869-4101 | |
dc.identifier.doi | 10.1186/s13244-020-00905-3 | |
dc.description.abstract | Breast cancer (BC) is the most common female cancer and the second cause of death among women worldwide. The 5-year relative survival rate recently improved up to 90% due to increased population coverage and women's attendance to organised mammography screening as well as to advances in therapies, especially systemic treatments. Screening attendance is associated with a mortality reduction of at least 30% and a 40% lower risk of advanced disease. The stage at diagnosis remains the strongest predictor of recurrences. Systemic treatments evolved dramatically over the last 20 years: aromatase inhibitors improved the treatment of early-stage luminal BC; targeted monoclonal antibodies changed the natural history of anti-human epidermal growth factor receptor 2-positive (HER2) disease; immunotherapy is currently investigated in patients with triple-negative BC; gene expression profiling is now used with the aim of personalising systemic treatments. In the era of precision medicine, it is a challenging task to define the relative contribution of early diagnosis by screening mammography and systemic treatments in determining BC survival. Estimated contributions before 2000 were 46% for screening and 54% for treatment advances and after 2000, 37% and 63%, respectively. A model showed that the 10-year recurrence rate would be 30% and 25% using respectively chemotherapy or novel treatments in the absence of screening, but would drop to 19% and 15% respectively if associated with mammography screening. Early detection per se has not a curative intent and systemic treatment has limited benefit on advanced stages. Both screening mammography and systemic therapies continue to positively contribute to BC prognosis. | |
dc.format | Electronic | |
dc.format.extent | 105 - ? | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | SPRINGER WIEN | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.title | Do we still need breast cancer screening in the era of targeted therapies and precision medicine? | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2020-08-20 | |
rioxxterms.versionofrecord | 10.1186/s13244-020-00905-3 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
rioxxterms.licenseref.startdate | 2020-09-25 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Insights into imaging | |
pubs.issue | 1 | |
pubs.notes | No embargo | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research/Breast Cancer Clinical Research | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research/Breast Cancer Clinical Research | |
pubs.publication-status | Published | |
pubs.volume | 11 | |
pubs.embargo.terms | No embargo | |
icr.researchteam | Breast Cancer Clinical Research | |
dc.contributor.icrauthor | Battisti, Nicolo | |